3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Gemcitabine
26
Specimen Handling
20
130-nm albumin-bound paclitaxel
18
Magnetic Resonance Spectroscopy
13
Irinotecan
13
Biopsy
12
Fluorouracil
11
Leucovorin
10
Oxaliplatin
9
Cyclophosphamide
8
pembrolizumab
7
fludarabine
7
Albumin-Bound Paclitaxel
7
Cisplatin
6
Cetuximab
6
Nivolumab
5
durvalumab
4
Taxes
4
Radiosurgery
4
Pemetrexed
4
Capecitabine
4
zimberelimab
3
trastuzumab deruxtecan
3
olaparib
3
irinotecan sucrosofate
3
dehydroftorafur
3
aldesleukin
3
Radiotherapy
3
Immunoglobulin G
3
Exercise
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Blood Component Removal
×
30 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled